Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases

Taylor, Peter C., Choy, Ernest ORCID: https://orcid.org/0000-0003-4459-8609, Baraliakos, Xenofon, Szekanecz, Zoltan, Xavier, Ricardo M., Isaacs, John D., Strengholt, Sander, Parmentier, Julie M., Lippe, Ralph and Tanaka, Yoshiya 2024. Differential properties of Janus kinase inhibitors in the treatment of immune-mediated inflammatory diseases. Rheumatology 63 (2) , pp. 298-308. 10.1093/rheumatology/kead448

Preview

PDF - Published Version Available under License Creative Commons Attribution Non-commercial. Download (1MB) | Preview

Abstract

Janus kinases (JAKs) are a family of cytosolic tyrosine kinases that regulate cytokine signal transduction, including cytokines involved in a range of inflammatory diseases, such as RA, psoriasis, atopic dermatitis and IBD. Several small-molecule JAK inhibitors (JAKis) are now approved for the treatment of various immune-mediated inflammatory diseases. There are, however, key differences between these agents that could potentially translate into unique clinical profiles. Each JAKi has a unique chemical structure, resulting in a distinctive mode of binding within the catalytic cleft of the target JAK, and giving rise to distinct pharmacological characteristics. In addition, the available agents have differing selectivity for JAK isoforms, as well as off-target effects against non-JAKs. Other differences include effects on haematological parameters, DNA damage repair, reproductive toxicity and metabolism/elimination. Here we review the pharmacological profiles of the JAKis abrocitinib, baricitinib, filgotinib, peficitinib, tofacitinib and upadacitinib.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Schools > Medicine
Publisher:	Oxford University Press
ISSN:	1462-0324
Date of First Compliant Deposit:	5 October 2023
Date of Acceptance:	13 August 2023
Last Modified:	25 Mar 2024 15:08
URI:	https://orca.cardiff.ac.uk/id/eprint/162984

Citation Data

Cited 3 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item